

Ref. No. JPL/CS/1741/2021

Date : 26<sup>th</sup> October, 2021

To  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held today, i.e. 26<sup>th</sup> october, 2021 – Unaudited Standalone Financial Results for the quarter and half year ended on 30<sup>th</sup> September, 2021.**

Reg.: **Regulation 30(2) and 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of directors of the Company have approved the unaudited standalone financial results for the quarter and half year ended on 30<sup>th</sup> September, 2021 during their respective meetings held today, i.e. on 26<sup>th</sup> October, 2021.

The unaudited financial results for the quarter from 1<sup>st</sup> July, 2021 to 30<sup>th</sup> September, 2021 and half year from 1<sup>st</sup> April, 2021 to 30<sup>th</sup> September, 2021, prepared in the format specified under regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and duly signed is enclosed.


Also enclosed along with is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 30<sup>th</sup> September, 2021.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,

For Jenburkt Pharmaceuticals Ltd.,



ASHISH R. SHAH

Company Secretary and Compliance Officer

Encl.: As Stated Above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

**Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended on 30th Sept, 2021**

(Rs. in Lacs other than EPS)

		Particulars	Quarter Ended			Year To Date		Year Ended
			30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I		Revenue from Operations	3550.84	2717.98	3048.48	6268.82	4791.60	10929.42
II		Other Income	119.06	119.49	102.25	238.55	199.84	430.85
III		Total income (I + II)	3669.90	2837.47	3150.73	6507.37	4991.44	11360.27
IV		Expenses						
	(a)	Cost of Materials Consumed	264.16	279.19	158.18	543.35	291.91	678.01
	(b)	Purchase of Stock-in-trade	586.23	450.21	709.97	1036.44	1185.08	2013.43
	(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	46.52	-21.49	48.71	25.03	-134.99	318.39
	(d)	Employee benefit expenses	911.67	864.51	791.60	1776.18	1601.70	3237.71
	(e)	Finance Costs	10.91	10.31	12.35	21.22	23.50	47.37
	(f)	Depreciation and Amortisation Expense	45.35	43.41	50.57	88.76	99.98	203.54
	(g)	Other expenses	715.41	609.55	622.91	1324.96	1068.06	2697.65
		Total Expenses (IV)	2580.25	2235.69	2394.29	4815.94	4135.24	9196.10
V		Profit before tax (III - IV)	1089.65	601.78	756.44	1691.43	856.20	2164.17
VI		Tax Expense						
	(i)	Current Tax	300.00	150.00	200.00	450.00	230.00	544.50
	(ii)	Income Tax for previous years	0.00	-7.21	0.00	-7.21	8.51	8.51
	(iii)	Deferred Tax	-7.39	-6.10	-10.76	-13.49	-50.31	-39.08
VII		Profit after tax for the period (V-VI)	797.04	465.09	567.20	1262.13	668.00	1650.24
VIII		Other Comprehensive Income						
	A (i)	Items that will not be reclassified to profit or loss	62.56	46.07	26.78	108.63	100.00	219.54
	(ii)	Income Tax relating to Items that will not be reclassified to profit or loss	-7.07	-5.30	5.38	-12.37	18.06	-23.58
	B (i)	Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii)	Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX		Total Comprehensive Income for the period (VII + VIII)	852.53	505.86	599.36	1358.39	786.06	1846.20
		Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94	458.94	458.94
X		Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	17.37	10.13	12.36	27.50	14.56	35.96

**Notes:**

- The above statement of unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26th October, 2021.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with the figures of the current period.
- The Statement of Assets And Liabilities and Cashflow Statement as at 30th Sept 2021 are annexed as Annexure A & B respectively.

 Place : Mumbai  
 Date : 26th October, 2021

 By order of the Board  
 For Jenburkt Pharmaceuticals Ltd.

  
 (Ashish U. Bhuta)  
 Chairman & Managing Director

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai



Annexure - A  
Statement of Standalone Assets & Liabilities

Rs in Lacs

	Particulars	30/09/2021	31/03/2021
		Amount	Amount
	<b>ASSETS</b>		
(1)	<b>Non-current Assets</b>		
(a)	Property, Plants & Equipments	856.47	850.69
(b)	Right to Use Asset	135.02	156.22
(c)	Goodwill	0.14	0.14
(d)	Other Intangible assets	37.17	47.96
(e)	Capital Work In Progress	360.31	37.76
(f)	Financial Assets		
(i)	Investments	761.72	650.07
(ii)	Loans	15.81	8.14
(iii)	Other Financial Assets	3,525.88	2,285.78
(g)	Other Non-current Assets	13.14	9.10
(2)	<b>Current assets</b>		
(a)	Inventories	792.69	758.15
(b)	Financial Assets		
(i)	Investments	1.74	25.22
(ii)	Trade Receivables	1,525.02	1,400.07
(iii)	Cash and Cash Equivalents	348.22	249.37
(iv)	Bank Balance other than (iii)	4,555.04	5,401.31
(v)	Loans	38.70	11.15
(vi)	Other Financial Assets	34.61	29.95
(c)	Other Current Assets	87.25	116.92
	<b>Total Assets</b>	<b>13,088.92</b>	<b>12,038.00</b>
	<b>EQUITY AND LIABILITIES</b>		
(1)	<b>Equity</b>		
(a)	Equity Share Capital	458.94	458.94
(b)	Other Equity - Reserves & Surplus	10,277.96	9,387.69
	<b>LIABILITIES</b>		
(2)	<b>Non-current liabilities</b>		
(a)	Financial Liabilities		
(i)	Lease Liabilities	71.86	93.97
(ii)	Other Financial Liabilities	296.47	296.47
(b)	Deferred Tax Liability (Net)	7.21	8.32
(3)	<b>Current Liabilities</b>		
(a)	Financial Liabilities		
(i)	Lease Liabilities	43.35	41.66
(ii)	Borrowings	272.16	371.06
(iii)	Trade Payables		
(A)	Total Outstanding dues of Micro Enterprises and Small Enterprises; and	10.12	2.66
(B)	Total Outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	614.10	358.56
(iv)	Other Financial Liabilities	541.26	650.95
(b)	Other Current Liabilities	194.51	227.02
(c)	Provisions	173.43	127.29
(d)	Current Tax Liabilities (Net)	127.57	13.41
	<b>Total Equity and Liabilities</b>	<b>13,088.92</b>	<b>12,038.00</b>

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.



(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai

Date : 26th October, 2021



**Annexure - B**  
**Cashflow Statement as on 30th September, 2021**

Rs in Lacs

		30-09-2021	31-03-2021
<b>A.</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES :</b>		
<b>a</b>	<b>Net Profit After Tax</b>	<b>1,262.13</b>	<b>1,650.24</b>
	Adjustments for :		
<b>i</b>	Depreciation and Amortisation Expense	88.76	203.54
<b>ii</b>	Profit on sale/written off of property, plant and equipment and intangible assets, net	(0.54)	(0.17)
<b>iii</b>	Tax Expense	429.30	513.93
<b>iv</b>	Finance Cost	21.22	47.37
<b>v</b>	Interest Income	(218.60)	(405.26)
<b>vi</b>	Dividend income	(0.65)	(1.82)
<b>vii</b>	Gain on sale of Investment (Short/Long Term Capital Gain)	-	(0.08)
<b>viii</b>	Provision/write off for doubtful trade receivables/advances	7.24	19.20
<b>ix</b>	Net unrealised foreign exchange gain	(13.56)	(22.21)
<b>x</b>	Others	(0.22)	(0.69)
	<b>Operating profit (Loss) before working capital changes</b>	<b>1,575.09</b>	<b>2,004.05</b>
<b>b</b>	<b>MOVEMENTS IN WORKING CAPITAL</b>		
<b>i</b>	Increase or (Decrease) in Inventories	(34.54)	331.72
<b>ii</b>	Increase or (Decrease) in Trade Receivables	(132.19)	363.70
<b>iii</b>	Increase or (Decrease) in Other (Current & Non Current) Assets	20.02	(11.11)
<b>iv</b>	Increase or (Decrease) in Trade Payables	262.99	(161.42)
<b>v</b>	Increase or (Decrease) in Bank Borrowings	(98.91)	27.17
<b>vi</b>	Increase or (Decrease) in Other (Current & Non Current) Liabilities	(128.64)	92.08
<b>vii</b>	Increase or (Decrease) in Provisions	46.14	(117.07)
<b>c</b>	<b>Cash used in operation</b>	<b>1,509.97</b>	<b>2,529.12</b>
<b>i</b>	Income Taxes paid (Net of Refund)	(328.64)	(583.65)
	<b>Net cash used in operating activities (A)</b>	<b>1,181.34</b>	<b>1,945.48</b>
<b>B.</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES :</b>		
<b>i</b>	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	(386.15)	(114.51)
<b>ii</b>	Proceeds from disposal of property, plant and equipment and intangible assets	1.58	2.97
<b>iii</b>	Purchase of Investments	(0.08)	(93.28)
<b>iv</b>	Proceeds from Sale / Redemption of Investments	20.76	72.06
<b>v</b>	Other Bank balances not considered as cash and cash equivalents		
	Bank Fixed Deposit made during the year	(6,154.03)	(10,909.16)
	Bank Fixed Deposit matured during the year	5,732.50	8,782.59
<b>vi</b>	Current & Non Current Financial Loans (Net employee loans given / recovered)	(35.22)	9.53
<b>vii</b>	Interest Received	258.74	369.88
<b>ix</b>	Dividend Received	0.65	1.82
	<b>Net cash generated by investing activities (B)</b>	<b>(561.25)</b>	<b>(1,878.10)</b>
<b>C.</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES :</b>		
<b>i</b>	Finance Cost	(16.14)	(34.83)
<b>ii</b>	Dividend paid	(479.60)	14.42
<b>iii</b>	Repayment of Lease Liabilities	(25.50)	(51.00)
	<b>Net cash used in financing activities (C)</b>	<b>(521.24)</b>	<b>(71.41)</b>
	<b>NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)</b>	<b>98.85</b>	<b>(4.03)</b>
	Cash and cash equivalent at the beginning of the year (1st April, 2021)	249.37	253.40
	Cash and cash equivalent as at the end of the half year (30th September, 2021)	348.22	249.37
		<b>98.85</b>	<b>(4.03)</b>

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.

  
(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai  
Date : 26th October, 2021



# D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9<sup>TH</sup> FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: [info@drmehta.in](mailto:info@drmehta.in), [vikram@drmehta.in](mailto:vikram@drmehta.in), [ashok@drmehta.in](mailto:ashok@drmehta.in)

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30<sup>th</sup> September 2021 ('the statement').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,  
Chartered Accountants  
(Firm Reg. No. 106207W)



Partner  
Ashok Mehta  
(Membership No. 101746)



UDIN: 21101746AAAA9U7119

Place: Mumbai